Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database
{{output}}
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy has changed the therapeutic landscape of relapsed/refractory multiple myeloma (RRMM). Despite the efficacy, these products have been associated with an adverse effect pr... ...
